Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells

Biomedicine and Pharmacotherapy

Volumn 65, Issue 3, 2011, Pages 183-192

  Huang, Zhenglan ^a   Ji, Maosheng ^a   Peng, Zhi ^a   Huang, Shifeng ^a   Xiao, Qing ^a   Li, Chunli ^a   Zeng, Jianming ^a   Gao, Miao ^a   Feng, Wenli ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic myeloid leukemia; Oligomerization; TAT peptide

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; TAT PROTEIN COILED COIL HEMAGLUTININ FUSION PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; DRUG PURIFICATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LASER SCANNING CYTOMETRY; OLIGOMERIZATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL DIVISION; CYTOPLASM; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC;

EID: 79959660843     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.02.013     Document Type: Article

References (27)

1. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
2. Cortes J.E., Kantarjian H.M., Goldberg S.L., Powell B.L., Giles F.J., Wetzler M., et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009, 27(28):4754-4759.
3. Soverini S., Gnani A., Colarossi S., Castagnetti F., Abruzzese E., Paolini S., et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009, 114(10):2168-2171.
4. Milojkovic D., Apperley J. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clin Cancer Res 2009, 15(24):7519-7527.
5. Heisterkamp N., Stam K., Groffen J., de Klein A., Grosveld G. Structural organization of the bcr gene and its role in the Ph[prime] translocation. Nature 1985, 315(6022):758-761.
6. Zhao X., Ghaffari S., Lodish H., Malashkevich V.N., Kim P.S. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol 2002, 9(2):117-120.
7. He Y. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 2002, 99(8):2957-2968.
8. Zhang X., Subrahmanyam R., Wong R., Gross A.W., Ren R. The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol Cell Biol 2001, 21(3):840-853.
9. McWhirter J.R., Galasso D.L., Wang J.Y.J. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993, 13:7587-7595.
10. Tauchi T., Okabe S., Miyazawa K., Ohyashiki K. The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells. Int J Oncol 1998, 12(6):1269-1276.
11. Beissert T. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood 2003, 102(8):2985-2993.
12. Green M., Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988, 55(6):1179-1188.
13. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55(6):1189-1193.
14. Herce H.D., Garcia A.E. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci 2007, 104(52):20805-20810.
15. Vive's E., Brodin P., Lebleu B. A truncated HIV-1 TAT protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997, 272:16010-16017.
16. Kato D., Miyazawa K., Ruas M., Starborg M., Wada I., Oka T., et al. Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts. FEBS Lett 1998, 427(2):203-208.
17. Ezhevsky S.A., Ho A., Becker-Hapak M., Davis P.K., Dowdy S.F. Differential regulation of retinoblastoma tumor suppressor protein by G1 cyclin-dependent kinase complexes in vivo. Mol Cell Biol 2001, 21(14):4773-4784.
18. Caron N.J., Torrente Y., Camirand G., Bujold M., Chapdelaine P., Leriche K., et al. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol Ther 2001, 3(3):310-318.
19. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285(5433):1569-1572.
20. Rapoport M., Lorberboum-Galski H. TAT-based drug delivery system - new directions in protein delivery for new hopes?. Expert Opin Drug Deliv 2009, 6(5):453-463.
21. Nagahara H., Vocero-Akbani A.M., Snyder E.L., Ho A., Latham D.G., Lissy N.A., et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998, 4(12):1449-1452.
22. Kaul R., Afzalpurkar A., Gupta S.K. Expression of bonnet monkey (Macaca radiata) zona pellucida-3 (ZP3) in a prokaryotic system and its immunogenicity. Mol Reprod Dev 1997, 47(2):140-147.
23. Albarran B., To R., Stayton P.S. A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells. Protein Eng Des Sel 2005, 18(3):147-152.
24. Jiang L., Ma Y., Wang J., Tao X., Wei D. The transduction of His-TAT-p53 fusion protein into the human osteogenic sarcoma cell line (Saos-2) and its influence on cell cycle arrest and apoptosis. Mol Biol Rep 2008, 35(1):1-8.
25. Koppelhus U., Awasthi S.K., Zachar V., Holst H.U., Ebbesen P., Nielsen P.E. Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev 2002, 12(2):51-63.
26. Jabbour E., Kantarjian H.M., Jones D., Shan J., O'Brien S., Reddy N., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, 113:2154-2160.
27. Strout M.P., Schatz D.G. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation aiding the way. Cancer Cell 2009, 16(3):174-176.